MX392203B - Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico - Google Patents
Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoicoInfo
- Publication number
- MX392203B MX392203B MX2020005113A MX2020005113A MX392203B MX 392203 B MX392203 B MX 392203B MX 2020005113 A MX2020005113 A MX 2020005113A MX 2020005113 A MX2020005113 A MX 2020005113A MX 392203 B MX392203 B MX 392203B
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydrospiro
- methoxypyridin
- piperidine
- oxo
- carbonyl
- Prior art date
Links
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 title abstract 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 abstract 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 abstract 2
- 108010018763 Biotin carboxylase Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000004684 trihydrates Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona la sal tris de ácido 4-(4-(1-isopropil-7-oxo-1,4,6,7- tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico como un anhidro cristalino o trihidrato; así como polimorfos, composiciones 5 farmacéuticas, formas de dosificación y su uso en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una(s) enzima(s) de acetil-CoA carboxilasa (ACC) en un animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589256P | 2017-11-21 | 2017-11-21 | |
| PCT/IB2018/058966 WO2019102311A1 (en) | 2017-11-21 | 2018-11-14 | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020005113A MX2020005113A (es) | 2022-05-11 |
| MX392203B true MX392203B (es) | 2025-03-21 |
Family
ID=64559730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005113A MX392203B (es) | 2017-11-21 | 2018-11-14 | Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11325909B2 (es) |
| EP (1) | EP3713942B8 (es) |
| JP (1) | JP7237082B2 (es) |
| KR (1) | KR102395451B1 (es) |
| CN (1) | CN111406056B (es) |
| AU (1) | AU2018372109B2 (es) |
| BR (1) | BR112020008413A2 (es) |
| CA (1) | CA3082867C (es) |
| DK (1) | DK3713942T3 (es) |
| ES (1) | ES2942463T3 (es) |
| FI (1) | FI3713942T3 (es) |
| HU (1) | HUE061885T2 (es) |
| IL (2) | IL274820B2 (es) |
| MX (1) | MX392203B (es) |
| PL (1) | PL3713942T3 (es) |
| PT (1) | PT3713942T (es) |
| RU (1) | RU2020116458A (es) |
| SG (1) | SG11202003600QA (es) |
| SI (1) | SI3713942T1 (es) |
| TW (1) | TWI703143B (es) |
| WO (1) | WO2019102311A1 (es) |
| ZA (1) | ZA202002566B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Nash/nafldおよび関連疾患の治療のための組合せ |
| CA3140972C (en) * | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
| CN117940422A (zh) | 2021-08-31 | 2024-04-26 | 辉瑞大药厂 | 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸,1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| UA102336C2 (uk) | 2009-11-10 | 2013-06-25 | Пфайзер Інк. | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ |
| DK2621493T3 (en) | 2010-09-30 | 2016-10-24 | Pfizer | N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS |
| CN103189377B (zh) | 2010-10-29 | 2015-02-25 | 辉瑞大药厂 | N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂 |
| EA022375B1 (ru) * | 2011-04-22 | 2015-12-30 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
-
2018
- 2018-11-14 EP EP18811658.6A patent/EP3713942B8/en active Active
- 2018-11-14 HU HUE18811658A patent/HUE061885T2/hu unknown
- 2018-11-14 CA CA3082867A patent/CA3082867C/en active Active
- 2018-11-14 PT PT188116586T patent/PT3713942T/pt unknown
- 2018-11-14 DK DK18811658.6T patent/DK3713942T3/da active
- 2018-11-14 IL IL274820A patent/IL274820B2/en unknown
- 2018-11-14 FI FIEP18811658.6T patent/FI3713942T3/fi active
- 2018-11-14 WO PCT/IB2018/058966 patent/WO2019102311A1/en not_active Ceased
- 2018-11-14 US US16/765,350 patent/US11325909B2/en active Active
- 2018-11-14 SI SI201830907T patent/SI3713942T1/sl unknown
- 2018-11-14 AU AU2018372109A patent/AU2018372109B2/en active Active
- 2018-11-14 CN CN201880075399.6A patent/CN111406056B/zh active Active
- 2018-11-14 IL IL313710A patent/IL313710A/en unknown
- 2018-11-14 SG SG11202003600QA patent/SG11202003600QA/en unknown
- 2018-11-14 RU RU2020116458A patent/RU2020116458A/ru unknown
- 2018-11-14 PL PL18811658.6T patent/PL3713942T3/pl unknown
- 2018-11-14 ES ES18811658T patent/ES2942463T3/es active Active
- 2018-11-14 BR BR112020008413-1A patent/BR112020008413A2/pt unknown
- 2018-11-14 JP JP2020545003A patent/JP7237082B2/ja active Active
- 2018-11-14 MX MX2020005113A patent/MX392203B/es unknown
- 2018-11-14 KR KR1020207014134A patent/KR102395451B1/ko active Active
- 2018-11-16 TW TW107140741A patent/TWI703143B/zh active
-
2020
- 2020-05-08 ZA ZA2020/02566A patent/ZA202002566B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005113A (es) | Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4' -piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico. | |
| BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| CL2022000763A1 (es) | Derivados de 2-isoindol-1,3,4-oxadiazol útiles como inhibidores de la histona desacetilasa 6 (hdac6) | |
| CY1118016T1 (el) | ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ | |
| BR112016026809A2 (pt) | compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| UY37363A (es) | Sulfonilureas y compuestos relacionados y sus usos | |
| ECSP13013024A (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| CL2017001686A1 (es) | 5-fluoro-4-imino-3-(alquil/alquil sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona como tratamiento de semillas. | |
| UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CO7170153A2 (es) | Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
| CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
| UY37164A (es) | Derivados de piridino-/pirimidino-piridino herbicidas | |
| AR106257A1 (es) | 3-fenilpirrolidina-2,4-dionas sustituidas con alquinilo y su uso como herbicidas | |
| CO2017000443A2 (es) | Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa | |
| UY36263A (es) | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso | |
| UY37163A (es) | Derivados de piridino-/pirimidino-piridino herbicidas | |
| AR109012A1 (es) | Sistema de administración transdérmica que contiene galantamina o sales de esta | |
| MX389589B (es) | Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros. |